Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease and/or Type II Diabetes
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe (Primary) ; Simvastatin
- Indications Coronary artery disease; Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon; Schering-Plough
- 22 Apr 2008 New trial record.